SG Americas Securities LLC Has $4.09 Million Holdings in Prestige Consumer Healthcare Inc. $PBH

SG Americas Securities LLC trimmed its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 20.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 66,325 shares of the company’s stock after selling 17,114 shares during the period. SG Americas Securities LLC owned approximately 0.14% of Prestige Consumer Healthcare worth $4,092,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of Prestige Consumer Healthcare by 4.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock valued at $161,723,000 after buying an additional 119,459 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Prestige Consumer Healthcare by 4.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock worth $100,893,000 after acquiring an additional 70,376 shares in the last quarter. Westwood Holdings Group Inc. increased its stake in Prestige Consumer Healthcare by 2.4% in the second quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock valued at $70,420,000 after acquiring an additional 20,626 shares during the last quarter. Bank of America Corp DE increased its stake in Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after acquiring an additional 115,459 shares during the last quarter. Finally, Raymond James Financial Inc. raised its position in Prestige Consumer Healthcare by 15.7% during the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock valued at $39,807,000 after purchasing an additional 86,373 shares in the last quarter. 99.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on PBH. Jefferies Financial Group cut their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $76.50.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the transaction, the vice president directly owned 41,048 shares in the company, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $52.47 on Friday. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of 13.88, a PEG ratio of 1.72 and a beta of 0.47. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The business’s 50-day moving average price is $64.69 and its 200-day moving average price is $62.92. Prestige Consumer Healthcare Inc. has a 12 month low of $51.28 and a 12 month high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). The firm had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. During the same period in the prior year, the company earned $1.22 EPS. The business’s quarterly revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).